The relationship between cognitive impairment and superoxide dismutase activity in untreated first-episode patients with schizophrenia

References

• An H, Du X, Huang X, Qi L, Jia Q, Yin G, Xiao C, Huang X-F, Ning Y, Cassidy RM, et al. 2018. Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Transl Psychiatry. 8(1):1–7.
   PubMedGoogle Scholar
• Bai Z-L, Li X-S, Chen G-Y, Du Y, Wei Z-X, Chen X, Zheng G-E, Deng W, Cheng Y. 2018. Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci. 66(3):428–436.
   PubMed Web of Science ®Google Scholar
• Barch DM, Ceaser A. 2012. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 16(1):27–34.
   PubMed Web of Science ®Google Scholar
• Chien YL, Hwu HG, Hwang TJ, Hsieh MH, Liu CC, Lin-Shiau SY, Liu CM. 2020. Clinical implications of oxidative stress in schizophrenia: acute relapse and chronic stable phase. Prog Neuropsychopharmacol Biol Psychiatry. 99:109868.
   PubMed Web of Science ®Google Scholar
• Crawford A, Fassett RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, Coombes JS. 2012. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene. 501(2):89–103.
   PubMed Web of Science ®Google Scholar
• Falkai P, Schmitt A. 2019. The need to develop personalized interventions to improve cognition in schizophrenia. World Psychiatry. 18(2):170eng.
   PubMed Web of Science ®Google Scholar
• Gama CS, Salvador M, Andreazza AC, Kapczinski F, Belmonte-de-Abreu PS. 2006. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry. 30(3):512–515.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Liencres C, Tas C, Brown EC, Erdin S, Onur E, Cubukcoglu Z, Aydemir O, Esen-Danaci A, Brune M. 2014. Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition. BMC Psychiatry. 14:268eng.
   PubMed Web of Science ®Google Scholar
• Green MF, Horan WP, Lee J. 2019. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry. 18(2):146–161.
   PubMed Web of Science ®Google Scholar
• Green MF. 2016. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry. 77 Suppl 2(Suppl 2):8–11.
   PubMedGoogle Scholar
• Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Srinivas Bharath MM, Shankar SK. 2012. Effect of premortem and postmortem factors on the distribution and preservation of antioxidant activities in the cytosol and synaptosomes of human brains. Biopreserv Biobank. 10(3):253–265.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Strassnig MT. 2019. Cognition and disability in schizophrenia: cognition-related skills deficits and decision-making challenges add to morbidity. World Psychiatry. 18(2):165–167.
   PubMed Web of Science ®Google Scholar
• Huang TT, Carlson EJ, Kozy HM, Mantha S, Goodman SI, Ursell PC, Epstein CJ. 2001. Genetic modification of prenatal lethality and dilated cardiomyopathy in Mn superoxide dismutase mutant mice. Free Radic Biol Med. 31(9):1101–1110.
   PubMed Web of Science ®Google Scholar
• Huang TT, Leu D, Zou Y. 2015. Oxidative stress and redox regulation on hippocampal-dependent cognitive functions. Arch Biochem Biophys. 576:2–7.
   PubMed Web of Science ®Google Scholar
• Jordan W, Dobrowolny H, Bahn S, Bernstein H-G, Brigadski T, Frodl T, Isermann B, Lessmann V, Pilz J, Rodenbeck A, et al. 2018. Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. Eur Arch Psychiatry Clin Neurosci. 268(2):129–143.
   PubMed Web of Science ®Google Scholar
• Joseph N, Zhang-James Y, Perl A, Faraone SV. 2015. Oxidative stress and ADHD: a meta-analysis. J Atten Disord. 19(11):915–924.
   PubMed Web of Science ®Google Scholar
• Kishida KT, Klann E. 2007. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal. 9(2):233–244.
   PubMed Web of Science ®Google Scholar
• Knapp LT, Klann E. 2002. Role of reactive oxygen species in hippocampal long-term potentiation: contributory or inhibitory? J Neurosci Res. 70(1):1–7.
   PubMed Web of Science ®Google Scholar
• Lecardeur L, Meunier-Cussac S, Dollfus S. 2013. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment]. Encephale. 39 (Suppl 1):S64–S71.
   PubMedGoogle Scholar
• Leonard B, Maes M. 2012. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 36(2):764–785.
   PubMed Web of Science ®Google Scholar
• Maes M. 2011. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 35(3):664–675.
   PubMed Web of Science ®Google Scholar
• Man L, Lv X, Du XD, Yin G, Zhu X, Zhang Y, Soares JC, Yang XN, Chen X, Zhang XY. 2018. Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Res. 263:1–6.
   PubMed Web of Science ®Google Scholar
• Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, Mico JA, Fernandez M, Echevarria E, Sanjuan J, Elorza J, Gonzalez-Pinto A. 2012. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res. 137(1–3):66–72.
   PubMed Web of Science ®Google Scholar
• Martinez-Cengotitabengoa M, Mico JA, Arango C, Castro-Fornieles J, Graell M, Paya B, Leza JC, Zorrilla I, Parellada M, Lopez MP, et al. 2014. Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. Schizophr Res. 156(1):23–29.
   PubMed Web of Science ®Google Scholar
• Medalia A, Saperstein AM. 2013. Does cognitive remediation for schizophrenia improve functional outcomes? Curr Opin Psychiatry. 26(2):151–157.
   PubMed Web of Science ®Google Scholar
• Mihaljevic-Peles A, Bajs Janovic M, Sagud M, Zivkovic M, Janovic S, Jevtovic S. 2019. Cognitive deficit in schizophrenia: an overview. Psychiatria Danubina. 31(Suppl 2):139–142.
   PubMedGoogle Scholar
• Miljevic CD, Nikolic-Kokic A, Blagojevic D, Milovanovic M, Munjiza A, Jukic MM, Pesic V, Lecic-Tosevski D, Spasic MB. 2018. Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res. 269:746–752.
   PubMed Web of Science ®Google Scholar
• Muller GJ, Lassmann H, Johansen FF. 2007. Anti-apoptotic signaling and failure of apoptosis in the ischemic rat hippocampus. Neurobiol Dis. 25(3):582–593.
   PubMed Web of Science ®Google Scholar
• Nicolle MM, Gonzalez J, Sugaya K, Baskerville KA, Bryan D, Lund K, Gallagher M, McKinney M. 2001. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience. 107(3):415–431.
   PubMed Web of Science ®Google Scholar
• Oyanagui Y. 1984. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem. 142(2):290–296.
   PubMed Web of Science ®Google Scholar
• Paiatto LN, Silva FGD, Yamada AT, Tamashiro W, Simioni PU. 2018. Adoptive transfer of dendritic cells expressing CD11c reduces the immunological response associated with experimental colitis in BALB/c mice. PLoS One. 13(5):e0196994.
   PubMed Web of Science ®Google Scholar
• Piotrowski P, Kotowicz K, Rymaszewska J, Beszłej JA, Plichta P, Samochowiec J, Kalinowska S, Trześniowska-Drukała B, Misiak B. 2019. Allostatic load index and its clinical correlates at various stages of psychosis. Schizophr Res. 210:73–80.
   PubMed Web of Science ®Google Scholar
• Qiu LL, Ji MH, Zhang H, Yang JJ, Sun XR, Tang H, Wang J, Liu WX, Yang JJ. 2016. NADPH oxidase 2-derived reactive oxygen species in the hippocampus might contribute to microglial activation in postoperative cognitive dysfunction in aged mice. Brain Behav Immun. 51:109–118.
   PubMed Web of Science ®Google Scholar
• Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M. 2015. Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci Biobehav Rev. 48:10–21.
   PubMed Web of Science ®Google Scholar
• Randolph C, Tierney MC, Mohr E, Chase TN. 1998. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 20(3):310–319.
   PubMed Web of Science ®Google Scholar
• Reid MA, Salibi N, White DM, Gawne TJ, Denney TS, Lahti AC. 2019. 7T proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. Schizophr Bull. 45(1):180–189.
   PubMed Web of Science ®Google Scholar
• Sahakian BJ, Savulich G. 2019. Innovative methods for improving cognition, motivation and wellbeing in schizophrenia. World Psychiatry. 18(2):168–170.
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Imai H. 2017. Hydrogen peroxide produced by superoxide dismutase SOD-2 activates sperm in Caenorhabditis elegans. J Biol Chem. 292(36):14804–14813.
   PubMed Web of Science ®Google Scholar
• Salminen LE, Paul RH. 2014. Oxidative stress and genetic markers of suboptimal antioxidant defense in the aging brain: a theoretical review. Rev Neurosci. 25(6):805–819.
   PubMed Web of Science ®Google Scholar
• Sen A, Nelson TJ, Alkon DL, Hongpaisan J. 2018. Loss in PKC Epsilon causes downregulation of MnSOD and BDNF expression in neurons of Alzheimer’s disease hippocampus. J Alzheimers Dis. 63(3):1173–1189.
   PubMed Web of Science ®Google Scholar
• Talarowska M, Orzechowska A, Szemraj J, Su KP, Maes M, Gałecki P. 2014. Manganese superoxide dismutase gene expression and cognitive functions in recurrent depressive disorder. Neuropsychobiology. 70(1):23–28.
   PubMed Web of Science ®Google Scholar
• Thiels E, Urban NN, Gonzalez-Burgos GR, Kanterewicz BI, Barrionuevo G, Chu CT, Oury TD, Klann E. 2000. Impairment of long-term potentiation and associative memory in mice that overexpress extracellular superoxide dismutase. J Neurosci. 20(20):7631–7639.
   PubMed Web of Science ®Google Scholar
• Tunçel ÖK, Sarısoy G, Bilgici B, Pazvantoglu O, Çetin E, Ünverdi E, Avcı B, Böke Ö. 2015. Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res. 228(3):688–694.
   PubMed Web of Science ®Google Scholar
• Vidović B, Milovanović S, Đorđević B, Kotur-Stevuljević J, Stefanović A, Ivanišević J, Miljković M, Spasić S, Stojanović D, Pantović M. 2014. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. Psychiatria Danubina. 26(3):0–213.
   Web of Science ®Google Scholar
• Watson JB, Arnold MM, Ho YS, O'Dell TJ. 2006. Age-dependent modulation of hippocampal long-term potentiation by antioxidant enzymes. J Neurosci Res. 84(7):1564–1574.
   PubMed Web of Science ®Google Scholar
• Wei C, Sun Y, Chen N, Chen S, Xiu M, Zhang X. 2020. Interaction of oxidative stress and BDNF on executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology. 111:104473.
   PubMed Web of Science ®Google Scholar
• Weinberger DR. 2002. Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility. Eur Psychiatr. 17(S4):355s–362s.
   PubMedGoogle Scholar
• Wu JQ, Chen DC, Tan YL, Tan S, Wang Z, Yang F, Soares JC, Zhang XY. 2014. Association of altered CuZn superoxide dismutase and cognitive impairment in schizophrenia patients with tardive dyskinesia. J Psychiatr Res. 58:167–174.
   PubMed Web of Science ®Google Scholar
• Wu JQ, Chen DC, Tan YL, Tan SP, Wang ZR, Xiu MH, Yang FD, Zhang XY. 2014. Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity. Schizophr Res. 152(1):210–216.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang FXue, Liu J, Fu Y, Hu J, Chen Y, et al. 2012. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 36(1):34–38.
   PubMed Web of Science ®Google Scholar
• Xiu M-H, Wang D, Chen S, Du X-D, Chen D-C, Chen N, Wang Y-C, Yin G, Zhang Y, Tan Y-L, et al. 2018. Interleukin-3, symptoms and cognitive deficits in first-episode drug-naive and chronic medicated schizophrenia. Psychiatry Res. 263:147–153.
   PubMed Web of Science ®Google Scholar
• Zhang B-H, Tan Y-L, Zhang W-F, Wang Z-R, Yang G-G, Shi C, Zhang X-Y, Zhou D-F. 2009. Repeatable battery for the assessment of neuropsychological status as a screening test in Chinese: reliability and validity. Chinese Mental Health J. 28:865–869.
   Google Scholar
• Zhang XY, Chen DC, Tan YL, Tan SP, Wang ZR, Yang FD, Okusaga OO, Zunta-Soares GB, Soares JC. 2015. The interplay between BDNF and oxidative stress in chronic schizophrenia. Psychoneuroendocrinology. 51:201–208.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Xiu MH, Tan YL, Yang FD, Zhang LY, Zhang LY, Haile CN, Kosten TR. 2013. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J Psychiatr Res. 47(8):1049–1053.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR. 2014. Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls. Schizophr Bull. 40(3):592–601.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Du X, Yin G, Zhang Y, Chen D, Xiu M, Wang C, Zhang R, Cassidy RM, Ning Y, et al. 2018. Prevalence and clinical correlates of and cognitive function at the time of suicide attempts in first-episode and drug-naive patients with schizophrenia. J Clin Psychiatry. 79(4):17m11797.
   Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. 2003. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res. 117(1):85–88.
   PubMed Web of Science ®Google Scholar